MorphoSys and Proteros Biostructures Receive Research Grant

Analysis of Antibody-Antigen-Complex Structures to Allow More Efficient Engineering of Therapeutic Antibodies

13-Oct-2010 - MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural ...

MorphoSys Announces Acquisition of Sloning

Combination of Technologies Set to Increase Success Rates in Drug Development

11-Oct-2010 - MorphoSys AG announced the acquisition of Sloning BioTechnology GmbH. The transaction will make MorphoSys the sole source of Sloning's state-of-the-art Slonomics technology, which improves the assembly and quality of protein libraries. By integrating Slonomics into its existing antibody ...

MorphoSys Strengthens Patent Position on its Core HuCAL Technology in Europe

17-Mar-2009 - MorphoSys AG announced that the European Patent Office has granted a European divisional patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the Company's core technology. The new patent (EP1143006) captures HuCAL's ...

Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich

28-Feb-2008 - Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary ...

MorphoSys und Astellas beginnen Antikörperpartnerschaft

Dritte therapeutische Allianz für MorphoSys in Japan

29-Mar-2007 - Die MorphoSys AG gab die Unterzeichnung eines Lizenzvertrags zur Nutzung der firmeneigenen HuCAL-Technologie mit Astellas Pharma Inc. bekannt. Im Rahmen der Vereinbarung gewährt MorphoSys Astellas Zugang zur seiner HuCAL GOLD-Antikörperbibliothek für den Einsatz in Astellas' pharmazeutischer ...

Forscher der japanischen Hokkaido Universität untersuchen Parkinson und Alzheimer-Entstehung mit HuCAL-Antikörpern

11-Dec-2006 - AbD Serotec, eine Geschäftseinheit der MorphoSys AG, gab die Ergebnisse einer Untersuchung der Hokkaido Universität mit Forschungsantikörper aus der HuCAL GOLD-Antikörperbibliothek von MorphoSys bekannt. Die vollständig menschlichen, monoklonalen Mini-Antikörper aus der hochdurchsatzfähigen ...

MorphoSys Expands Collaboration With Centocor

06-Jan-2005 - MorphoSys AG announced the extension of its agreement with Centocor Inc., a Johnson & Johnson company, until the end of 2007. The objective of the cooperation between MorphoSys and Centocor is the development of fully human therapeutic antibodies in a broad range of indications. The cooperation ...